Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [12/30/2025 14:55 PST] Bright Minds Biosciences Inc. (OTC:DRUG), Down By 100% ($93.99) From $93.99 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [12/17/2025 07:02 PST] DRUG Expected to Trade Down After Bearish Patterns Develop
• [12/11/2025 14:55 PST] Bright Minds Biosciences Inc. (OTC:DRUG), Up By 100% ($70) From $70 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [12/09/2025 07:16 PST] DRUG Expected to Trade Up After Bullish Patterns Develop
• [12/01/2025 06:58 PST] DRUG Expected to Trade Up After Bullish Patterns Develop
• [11/10/2025 07:39 PST] DRUG Expected to Trade Up After Bullish Patterns Develop